Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib in Advanced Melanoma
NCT01551693Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ganetespib in melanoma (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: 6-month Progression-Free Survival Rate. Started Sep 2011; status: terminated.
02
Drugs
ganetespib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01551693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01551693.